Seek Returns

BIIB vs. INCY: Biogen vs. Incyte Stock Comparison

How do Biogen (BIIB) and Incyte (INCY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and Incyte (INCY) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Biogen (BIIB) and Incyte (INCY)
Profile ItemBIIBINCY
NameBiogen Inc.Incyte Corp.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization36.71 billion USD24.39 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateSeptember 17, 1991November 4, 1993
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIIB
INCY
GSPC
Loading price history…
Biogen (BIIB) vs. Incyte (INCY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Biogen (BIIB) and Incyte (INCY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Biogen (BIIB) and Incyte (INCY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
Total Return (1Y)65.44%14.06%
Total Return (3Y, Annualized)4.62%32.03%
Total Return (5Y, Annualized)-0.96%12.69%

Risk Profile

Drawdown History

BIIB
INCY
GSPC
Loading price history…
Biogen (BIIB) vs. Incyte (INCY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Biogen (BIIB) and Incyte (INCY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
Volatility (1Y, Annualized)34.58%33.19%
Beta (5Y)0.080.78
Max Drawdown (5Y)-64.35%-40.50%
Avg. Volume (3M)1.05M1.58M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIIB and INCY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
Sharpe Ratio (1Y)1.770.29
Sortino Ratio (1Y)2.770.46

Profitability

ROE (TTM)

Incyte (INCY) at 7.84% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for INCY.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max
109.18%
Q3
6.23%
BIIB
1.87%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.84%

Max
109.18%
INCY
7.84%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Incyte (INCY) at 6.71% retains a top-quartile share of revenue as profit, ahead of Biogen (BIIB) at 3.38%, which keeps about the industry-typical share.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max
18.05%
Q3
4.78%
BIIB
3.38%
Median
0.00%
Q1
-4.14%
Min
-17.05%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.71%

Max
18.05%
INCY
6.71%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Biogen (BIIB) at 24.12% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max
83.12%
BIIB
24.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.72%

Max
83.12%
INCY
33.72%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
ROE (TTM)1.87%7.84%
ROA (TTM)4.94%17.78%
Net Margin (TTM)3.38%6.71%
Operating Margin (TTM)24.12%33.72%
Gross Margin (TTM)75.77%56.02%

Growth

Revenue Growth

Both Biogen (BIIB) at 2.22% and Incyte (INCY) at 21.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Biogen (BIIB) at -21.38%, which is closer to a typical peer reading.

Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
Revenue Growth (YoY)2.22%21.22%
Revenue Growth (3Y CAGR)-0.94%14.84%
EPS Growth (YoY)-21.38%4,173.33%
EPS Growth (3Y CAGR)-25.04%61.56%

Financial Strength

Current Ratio (MRQ)

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Biogen (BIIB) at 1.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BIIB.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BIIB
1.95
Min
0.10

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.84

Max
25.13
Q3
12.13
Median
5.52
INCY
3.84
Q1
2.47
Min
0.10
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Biogen (BIIB) at 0.41 runs a more typical debt-to-equity mix.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max
1.42
Q3
0.65
BIIB
0.41
Median
0.15
Q1
0.02
Min
0.00

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
INCY
0.01
Min
0.00
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
Current Ratio (MRQ)1.953.84
Debt / Equity (MRQ)0.410.01
Net Debt / EBITDA1.97-1.88

Dividends

Dividend Yield (TTM)

Neither Biogen (BIIB) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Biogen (BIIB) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Both look expensive on trailing earnings: Incyte (INCY) at 61.05 sits in the richer P/E ratio quartile, and Biogen (BIIB) at 107.51 is richer still, above its industry range.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB
107.51
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

61.05

Max
85.34
INCY
61.05
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Biogen (BIIB) at 3.57 and Incyte (INCY) at 4.06 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max
58.18
Q3
25.77
Median
7.30
BIIB
3.57
Q1
3.01
Min
0.01

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.06

Max
58.18
Q3
25.77
Median
7.30
INCY
4.06
Q1
3.01
Min
0.01
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Biogen (BIIB) at 1.94 and Incyte (INCY) at 4.33 are valued close to their industries’ norm against book — neither stands out from peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max
13.53
Q3
6.54
Median
3.25
BIIB
1.94
Q1
1.69
Min
-5.59

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.33

Max
13.53
Q3
6.54
INCY
4.33
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Biogen (BIIB) vs. Incyte (INCY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and Incyte (INCY)
MetricBIIBINCY
P/E Ratio (TTM)107.5161.05
P/S Ratio (TTM)3.574.06
P/B Ratio (MRQ)1.944.33
Free Cash Flow Yield (TTM)2.20%5.28%